Neurosetta’s Award-Winning Presentation at the 2024 ASCCT Annual Meeting
At the American Society for Cellular and Computational Toxicology's Annual [...]
Neurosetta at ISTNET-DART
Neurosetta participated and presented at the International Stakeholder Network- Developmental [...]
RosetteArray Collaboration Highlighted in CrestOptics’ Application Note
Neurosetta's RosetteArray collaboration with the Di'Angelantonio Lab at Universita di [...]
Neurosetta Featured in “Toxicologic Pathology”
In a recent publication from Toxicologic Pathology, Neurosetta's RosetteArray technology [...]
Neurosetta joins the 3Rs Collaborative’s Microphysiological Systems Initiative
Neurosetta joins the 3Rs Collaborative's Microphysiological Systems (MPS) Initiative. This working [...]
New technology developed at UW-Madison aims to detect developmental disorders before birth
Learn about RosetteArray on WKOW MADISON (WKOW) -- Professors and [...]
RosetteArray technology detects risk for Autism Spectrum Disorder
Read about Neurosetta in the University of Wisconsin-Madison News: Stem [...]
Neurosetta’s is the world-wide exclusive licensee of RosetteArray™ technology
As of September 2023, Neurosetta became the exclusive licensee of [...]
Randolph Ashton (Co-founder & CEO of Neurosetta) Inducted into the 2023 Class of the AIMBE College of Fellows
The American Institute for Medical and Biological Engineering (AIMBE) has [...]
Innovator of the Year Award
Randolph Ashton, PhD, co-founder and Chief Executive Officer of Neurosetta, [...]